Latest Insider Transactions at Allovir, Inc. (ALVR)
This section provides a real-time view of insider transactions for Allovir, Inc. (ALVR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Allovir, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Allovir, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2022
|
Jeffrey S Bornstein |
BUY
Open market or private purchase
|
Direct |
5,000
+12.44%
|
$40,000
$8.87 P/Share
|
|
Jan 25
2022
|
Ercem Atillasoy Officer |
SELL
Open market or private sale
|
Direct |
4,639
-4.42%
|
$37,112
$8.24 P/Share
|
|
Jan 24
2022
|
David Hallal |
SELL
Open market or private sale
|
Direct |
17,100
-0.77%
|
$136,800
$8.01 P/Share
|
|
Jan 20
2022
|
Vikas Sinha |
SELL
Open market or private sale
|
Direct |
6,450
-0.75%
|
$51,600
$8.75 P/Share
|
|
Jan 20
2022
|
Brett R Hagen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,563
-2.41%
|
$12,504
$8.75 P/Share
|
|
Jan 20
2022
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,656
-1.16%
|
$37,248
$8.75 P/Share
|
|
Jan 18
2022
|
Ann M. Leen Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,256
+31.21%
|
-
|
|
Jan 18
2022
|
Jeroen B Van Beek Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,256
+5.42%
|
-
|
|
Jan 18
2022
|
Diana Brainard Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
315,000
+37.67%
|
-
|
|
Jan 18
2022
|
Edward Miller General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,256
+9.67%
|
-
|
|
Jan 18
2022
|
Ercem Atillasoy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,256
+15.84%
|
-
|
|
Jan 18
2022
|
Vikas Sinha |
BUY
Grant, award, or other acquisition
|
Direct |
48,838
+5.11%
|
-
|
|
Jan 18
2022
|
Brett R Hagen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,442
+17.78%
|
-
|
|
Dec 02
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
514
-0.13%
|
$8,738
$17.06 P/Share
|
|
Nov 16
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,203
-3.63%
|
$319,263
$21.13 P/Share
|
|
Nov 16
2021
|
Ann M. Leen Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100
-0.0%
|
$2,100
$21.76 P/Share
|
|
Nov 15
2021
|
Ann M. Leen Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,122
-0.27%
|
$128,562
$21.92 P/Share
|
|
Nov 12
2021
|
Ann M. Leen Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
14,766
-0.32%
|
$324,852
$22.72 P/Share
|
|
Nov 10
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
800
-0.04%
|
$19,200
$24.77 P/Share
|
|
Nov 09
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
3,815
-0.2%
|
$91,560
$24.79 P/Share
|
|
Nov 05
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
8,381
-0.44%
|
$201,144
$24.8 P/Share
|
|
Oct 27
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
2,200
-0.12%
|
$52,800
$24.78 P/Share
|
|
Oct 25
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
7,769
-0.41%
|
$186,456
$24.82 P/Share
|
|
Oct 22
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
5,723
-0.3%
|
$137,352
$24.77 P/Share
|
|
Oct 21
2021
|
Ercem Atillasoy Officer |
SELL
Open market or private sale
|
Direct |
1,514
-1.42%
|
$36,336
$24.23 P/Share
|
|
Oct 21
2021
|
Morana Jovan Embiricos |
SELL
Open market or private sale
|
Indirect |
100
-0.01%
|
$2,400
$24.75 P/Share
|
|
Oct 04
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,689
-1.0%
|
$448,536
$24.74 P/Share
|
|
Oct 01
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,413
-0.81%
|
$85,325
$25.07 P/Share
|
|
Sep 30
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,171
-2.8%
|
$304,275
$25.17 P/Share
|
|
Sep 29
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.23%
|
$25,000
$25.04 P/Share
|
|
Sep 28
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,750
-0.79%
|
$90,000
$24.12 P/Share
|
|
Sep 17
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,950
-0.62%
|
$70,800
$24.01 P/Share
|
|
Sep 17
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,916
-1.34%
|
$147,900
$25.08 P/Share
|
|
Sep 15
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
800
-0.17%
|
$19,200
$24.03 P/Share
|
|
Sep 02
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
513
-0.12%
|
$9,747
$19.86 P/Share
|
|
Aug 17
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,205
-3.33%
|
$258,485
$17.82 P/Share
|
|
Jul 02
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,586
-3.73%
|
$353,134
$19.99 P/Share
|
|
Jun 03
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
508
-0.11%
|
$11,176
$22.87 P/Share
|
|
May 25
2021
|
Malcolm Brenner |
SELL
Bona fide gift
|
Indirect |
818,663
-100.0%
|
-
|
|
May 18
2021
|
Jeroen B Van Beek Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,201
-3.22%
|
$334,422
$22.8 P/Share
|
|
May 17
2021
|
Diana Brainard Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+45.21%
|
-
|
|
May 10
2021
|
Ann M. Leen Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
150,000
-6.1%
|
$3,300,000
$22.75 P/Share
|
|
Apr 05
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,212
-3.53%
|
$418,876
$23.89 P/Share
|
|
Mar 22
2021
|
Agustin Melian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,750
-0.72%
|
$93,750
$25.97 P/Share
|
|
Mar 16
2021
|
Ann M. Leen Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
3,025
-0.12%
|
$90,750
$30.0 P/Share
|
|
Mar 11
2021
|
John Robert Wilson Director |
SELL
Open market or private sale
|
Indirect |
16,662
-0.09%
|
$516,522
$31.25 P/Share
|
|
Mar 10
2021
|
John Robert Wilson Director |
SELL
Open market or private sale
|
Indirect |
72,743
-0.26%
|
$2,255,033
$31.61 P/Share
|
|
Mar 09
2021
|
John Robert Wilson Director |
SELL
Open market or private sale
|
Indirect |
110,595
-0.59%
|
$3,428,445
$31.5 P/Share
|
|
Mar 05
2021
|
Malcolm Brenner |
SELL
Open market or private sale
|
Indirect |
48,091
-1.13%
|
$1,538,912
$32.31 P/Share
|
|
Mar 04
2021
|
Malcolm Brenner |
SELL
Open market or private sale
|
Indirect |
49,598
-1.38%
|
$1,785,528
$36.03 P/Share
|